Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series

Aoki, Hiroshi; Matsumoto, Naoki; Takahashi, Hiroshi; Honda, Masaaki; Kaneko, Takeshi; Arima, Shuhei; Ishii, Tomotaka; Mizutani, Taku; Masuzaki, Ryota; Nirei, Kazushige; Yanagimoto, Hiroaki; Ogawa, Masahiro; Kanda, Tatsuo; Moriyama, Mitsuhiko; Miura, Katsuhiro

doi:10.21873/anticanres.15442

Cited by 6 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only one report has shown the efficacy of atezolizumab in HCC and esophageal cancer. 13 In that report, HCC treatment demonstrated a partial response and the esophageal cancer stabilized, and the patient remained healthy for 9 months with treatment.…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

The development of hepatocellular carcinoma during long-term treatment for recurrent non-small cell lung cancer: a case report

Kang²

2023

JLC

View full text Add to dashboard Cite

Multiple primary malignancies (MPMs) are defined as the presence of two or more malignancies in different organs, without a subordinate relationship. Although rarely reported, hepatocellular carcinoma (HCC) occasionally presents with simultaneous or metachronous primary malignancies in other organs. In this report, we describe a patient with lung adenocarcinoma and lymph node and bone metastases, treated with five chemotherapeutic regimens for 24 months. Changing the chemotherapy regimen based on the suspicion of metastasis of a new liver mass did not lead to improvements. This prompted a liver biopsy and a revised diagnosis of HCC. Sixth-line treatment with the concurrent use of cisplatin-paclitaxel for lung cancer and sorafenib for HCC, stabilized the disease. The concurrent treatment was not tolerated and was discontinued owing to adverse events. Considering our findings, treatment with increased efficacy and lower toxicity for MPMs is warranted.

show abstract

Section: Discussionmentioning

confidence: 88%

“… 14 Recently, the efficacy of nivolumab was reported in a patient with HCC and lung cancer. 13 Persistent partial response of HCC and lung cancer was sustained for 9 months.…”

Section: Discussionmentioning

confidence: 99%

The development of hepatocellular carcinoma during long-term treatment for recurrent non-small cell lung cancer: a case report

Kang²

2023

JLC

View full text Add to dashboard Cite

show abstract

“…To our knowledge, regarding ICI treatment for MPMs, there have been only a few case reports available and evidence-based studies are lacking. There are several immune checkpoint inhibitors, such as nivolumab, pembrolizumab, and atezolizumab, which have demonstrated encouraging efficacy in the treatment of multiple primary tumors (26)(27)(28)(29)(30). A bulk of studies have shown the favorable efficacy of ICIs on PSC (31)(32)(33) and HCC (34)(35)(36), respectively.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review

et al. 2022

View full text Add to dashboard Cite

BackgroundWith significant advances in the diagnostic tools and treatment modalities of cancer, the incidence of multiple primary malignancies (MPMs) has increased in the last decades. The therapeutic option changed with the arising of immune checkpoint inhibitors (ICIs), which have improved the survival of a broad spectrum of tumors. However, little information is available when it comes to the efficacy, resistance, and underlying mechanisms of ICIs.Case PresentationA 67-year-old woman was diagnosed with pulmonary sarcomatoid carcinoma (PSC) with a history of hepatocellular carcinoma (HCC) and viral hepatitis B. Following the lack of response to systemic chemotherapy, she was treated with camrelizumab, an anti-programmed cell death protein 1 monoclonal antibody, in combination with chemotherapy, and a partial response was obtained both in PSC and HCC. After a course of 9-month treatment, the PSC lesion shrank still, while HCC was evaluated as a progressive disease with an increase in the diameter of liver neoplasm, elevated alpha-fetoprotein, and enlarged abdominal lymph nodes. Then, with the addition of radiotherapy for abdominal metastasis, the lung lesion was continuously shrinking. In the meantime, the liver neoplasm and abdominal lymph nodes showed no significant enlargement.ConclusionCamrelizumab combination therapy could consistently benefit the MPM patients with PSC and HCC, which may be a promising option for patients with MPMs.

show abstract

Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma

Roozitalab,

Abedi,

Imani

et al. 2024

Cancer Metastasis Rev

View full text Add to dashboard Cite

Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series

Cited by 6 publications

References 14 publications

The development of hepatocellular carcinoma during long-term treatment for recurrent non-small cell lung cancer: a case report

The development of hepatocellular carcinoma during long-term treatment for recurrent non-small cell lung cancer: a case report

Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review

Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma

Contact Info

Product

Resources

About